Last reviewed · How we verify
Adrenocorticotropin
Adrenocorticotropin is a Small molecule drug developed by University of California, San Diego. It is currently in Phase 3 development. Also known as: Cosyntropin, ACTH.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Adrenocorticotropin |
|---|---|
| Also known as | Cosyntropin, ACTH |
| Sponsor | University of California, San Diego |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome (PHASE2)
- Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation (PHASE3)
- FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease (EARLY_PHASE1)
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer (PHASE2)
- AuriculoTherapy NeuroImaging (NA)
- CRF2 Agonist for the Treatment of Worsening Heart Failure (PHASE2)
- Use of Acthar in Rheumatoid Arthritis (RA) Related Flares (PHASE4)
- ACTH Stability on Whole Blood (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adrenocorticotropin CI brief — competitive landscape report
- Adrenocorticotropin updates RSS · CI watch RSS
- University of California, San Diego portfolio CI
Frequently asked questions about Adrenocorticotropin
What is Adrenocorticotropin?
Who makes Adrenocorticotropin?
Is Adrenocorticotropin also known as anything else?
What development phase is Adrenocorticotropin in?
Related
- Manufacturer: University of California, San Diego — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Cosyntropin, ACTH
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing